Expert insights from J+D Forecasting: How to model for loss of exclusivity and generic entrants

Is your company prepared for the ripple effects of a patent cliff, whether it’s your drug or a competitor’s? This expert report from J+D Forecasting, now part of Evaluate, explores how to factor these market shifts into your forecasting structure. When a pharmaceutical company patents a new drug, the business is granted an exclusive window […]

Share:

Download today








Is your company prepared for the ripple effects of a patent cliff, whether it’s your drug or a competitor’s? This expert report from J+D Forecasting, now part of Evaluate, explores how to factor these market shifts into your forecasting structure.

When a pharmaceutical company patents a new drug, the business is granted an exclusive window to sell that product at a premium to recoup R&D costs. Once the patent expires, however, generic manufacturers can enter the market, often triggering a sharp drop in the original product’s sales and influencing broader dynamics.

Download your copy and discover how to adapt your forecast model to:

  • Identify all current and future products of interest
  • Focus on those brands of greatest competitive threat
  • Tell a clear story of the landscape following a patent expiry

Upcoming Webinar

China Pipelines, Western Portfolios

Tuesday 14th July 3pm BST | 10am ET

Western pharma committed close to $2 billion in licensing deals and acquisitions for China-originated assets in Q1 2026 alone.

Related Content